BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tarif N, Bakris GL. Preservation of renal function: the spectrum of effects by calcium-channel blockers. Nephrol Dial Transplant. 1997;12:2244-2250. [PMID: 9394306 DOI: 10.1093/ndt/12.11.2244] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 1.9] [Reference Citation Analysis]
Number Citing Articles
1 Herlitz H, Harris K, Risler T, Boner G, Bernheim J, Chanard J, Aurell M. The effects of an ACE inhibitor and a calcium antagonist on the progression of renal disease: the Nephros Study. Nephrology Dialysis Transplantation 2001;16:2158-65. [DOI: 10.1093/ndt/16.11.2158] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 2.0] [Reference Citation Analysis]
2 Palmer BF. Impaired renal autoregulation: implications for the genesis of hypertension and hypertension-induced renal injury. Am J Med Sci 2001;321:388-400. [PMID: 11417753 DOI: 10.1097/00000441-200106000-00005] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 1.7] [Reference Citation Analysis]
3 Hebert LA, Wilmer WA, Falkenhain ME, Ladson-wofford SE, Nahman NS, Rovin BH. Renoprotection: One or many therapies? Kidney International 2001;59:1211-26. [DOI: 10.1046/j.1523-1755.2001.0590041211.x] [Cited by in Crossref: 122] [Cited by in F6Publishing: 84] [Article Influence: 6.1] [Reference Citation Analysis]
4 Robles NR, Fici F, Grassi G. Dihydropyridine calcium channel blockers and renal disease. Hypertens Res 2017;40:21-8. [DOI: 10.1038/hr.2016.85] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
5 Pasantes-Morales H, Quiroz H, Quesada O. Treatment with taurine, diltiazem, and vitamin E retards the progressive visual field reduction in retinitis pigmentosa: a 3-year follow-up study. Metab Brain Dis 2002;17:183-97. [PMID: 12322788 DOI: 10.1023/a:1019926122125] [Cited by in Crossref: 40] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
6 Nigbor DA, Lewis JB. Use of calcium antagonists in renal patients: Therapeutic benefit or medical malpractice? Current Science Inc 2003;5:430-6. [DOI: 10.1007/s11906-003-0090-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
7 Smith AC, Toto R, Bakris GL. Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy. Kidney International 1998;54:889-96. [DOI: 10.1046/j.1523-1755.1998.00055.x] [Cited by in Crossref: 75] [Cited by in F6Publishing: 52] [Article Influence: 3.3] [Reference Citation Analysis]
8 Ruilope LM, Campo C, Segura J. The calcium channel blocker controversy in patients with diabetic nephropathy: Is there an issue? Curr Hypertens Rep 2001;3:419-21. [PMID: 11551377 DOI: 10.1007/s11906-001-0060-4] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
9 Abbott KC, Bakris GL. What have we learned from the current trials? Medical Clinics of North America 2004;88:189-207. [DOI: 10.1016/s0025-7125(03)00129-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
10 Yatzidis H. Oral supplement of six selective amino acids arrest progression renal failure in uremic patients. Int Urol Nephrol 2004;36:591-8. [DOI: 10.1007/s11255-004-8782-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
11 Blanco S, Penin R, Casas I, López D, Romero R. Effects of antihypertensive drugs in experimental type 2 diabetes-related nephropathy. Kidney International 2002;62:S27-31. [DOI: 10.1046/j.1523-1755.62.s82.6.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
12 Susic D. Renal protective potential of antihypertensive drugs. Expert Opin Investig Drugs 2000;9:2593-600. [PMID: 11060822 DOI: 10.1517/13543784.9.11.2593] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
13 Kumagai H, Hayashi K, Kumamaru H, Saruta T. Amlodipine is comparable to angiotensin-converting enzyme inhibitor for long-term renoprotection in hypertensive patients with renal dysfunction: a one-year, prospective, randomized study. American Journal of Hypertension 2000;13:980-5. [DOI: 10.1016/s0895-7061(00)00287-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
14 Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hsueh W, Sowers J. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000;36:646-661. [PMID: 10977801 DOI: 10.1053/ajkd.2000.16225] [Cited by in Crossref: 939] [Cited by in F6Publishing: 679] [Article Influence: 44.7] [Reference Citation Analysis]
15 Wenzel RR. Renal protection in hypertensive patients: selection of antihypertensive therapy. Drugs 2005;65 Suppl 2:29-39. [PMID: 16398060 DOI: 10.2165/00003495-200565002-00005] [Cited by in Crossref: 37] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
16 Blanco S, Bonet J, López D, Casas I, Romero R. ACE inhibitors improve nephrin expression in Zucker rats with glomerulosclerosis. Kidney Int Suppl 2005;:S10-4. [PMID: 15613060 DOI: 10.1111/j.1523-1755.2005.09303.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 2.0] [Reference Citation Analysis]
17 Dentali F, Sharma AM, Douketis JD. Management of hypertension in overweight and obese patients: A practical guide for clinicians. Current Science Inc 2005;7:330-6. [DOI: 10.1007/s11906-005-0065-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
18 Bakris GL, Weir MR, Secic M, Campbell B, Weis-mcnulty A. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney International 2004;65:1991-2002. [DOI: 10.1111/j.1523-1755.2004.00620.x] [Cited by in Crossref: 145] [Cited by in F6Publishing: 100] [Article Influence: 8.5] [Reference Citation Analysis]
19 Attridge RL, Linn WD, Ryan L, Koeller J, Frei CR. Evaluation of the incidence and risk factors for development of fenofibrate-associated nephrotoxicity. J Clin Lipidol 2012;6:19-26. [PMID: 22264570 DOI: 10.1016/j.jacl.2011.08.008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
20 Gojaseni P, Phaopha A, Chailimpamontree W, Pajareya T, Chittinandana A. Prevalence and risk factors of microalbuminuria in Thai nondiabetic hypertensive patients. Vasc Health Risk Manag 2010;6:157-65. [PMID: 20448800 DOI: 10.2147/vhrm.s9739] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
21 Bakris GL, Sowers JR. Microalbuminuria in diabetes: focus on cardiovascular and renal risk reduction. Curr Diab Rep 2002;2:258-62. [PMID: 12643182 DOI: 10.1007/s11892-002-0092-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
22 Christensen PK, Hommel EE, Clausen P, Feldt-rasmussen B, Parving H. Impaired autoregulation of the glomerular filtration rate in patients with nondiabetic nephropathies. Kidney International 1999;56:1517-23. [DOI: 10.1046/j.1523-1755.1999.00676.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 1.6] [Reference Citation Analysis]
23 Bjørn-Yoshimoto WE, Ramiro IBL, Yandell M, McIntosh JM, Olivera BM, Ellgaard L, Safavi-Hemami H. Curses or Cures: A Review of the Numerous Benefits Versus the Biosecurity Concerns of Conotoxin Research. Biomedicines 2020;8:E235. [PMID: 32708023 DOI: 10.3390/biomedicines8080235] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
24 Segura J, García-donaire JA, Ruilope LM. Are differences in calcium antagonists relevant across all stages of nephropathy or only proteinuric nephropathy? Current Opinion in Nephrology & Hypertension 2007;16:422-6. [DOI: 10.1097/mnh.0b013e328285dfc4] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
25 Bakris GL, Weir MR, Dequattro V, Mcmahon FG. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney International 1998;54:1283-9. [DOI: 10.1046/j.1523-1755.1998.00083.x] [Cited by in Crossref: 195] [Cited by in F6Publishing: 138] [Article Influence: 8.5] [Reference Citation Analysis]
26 Makrilakis K, Bakris G. Diabetic Hypertensive Patients: Improving Their Prognosis: . Journal of Cardiovascular Pharmacology 1998;31:S34-40. [DOI: 10.1097/00005344-199800002-00006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
27 González-albarrán O, Robles RG, Ruilope LM. Therapeutic implications and new perspectives for essential hypertension and renal damage. Kidney International 1998;54:S46-50. [DOI: 10.1046/j.1523-1755.1998.06812.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
28 Basta E, Bakris GL. Evolution of Drugs That Preserve Renal Function. The Journal of Clinical Pharmacology 2013;40:978-89. [DOI: 10.1177/00912700022009701] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
29 Rizos CV. Manidipine: A different dihydropyridine. WJH 2011;1:3. [DOI: 10.5494/wjh.v1.i1.3] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
30 Ruilope LM, Campo C, Rodicio JL. Blood pressure control, proteinuria and renal outcome in chronic renal failure: . Current Opinion in Nephrology and Hypertension 1998;7:145-8. [DOI: 10.1097/00041552-199803000-00001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
31 Garg JP, Bakris GL. Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. Vasc Med 2002;7:35-43. [PMID: 12083733 DOI: 10.1191/1358863x02vm412ra] [Cited by in Crossref: 187] [Cited by in F6Publishing: 141] [Article Influence: 10.4] [Reference Citation Analysis]
32 Zou Z, Xu F, Wang L, An M, Zhang H, Shi X. Antihypertensive and renoprotective effects of trandolapril/verapamil combination: a meta-analysis of randomized controlled trials. J Hum Hypertens 2011;25:203-10. [DOI: 10.1038/jhh.2010.60] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
33 Robles NR. Calcium Antagonists and Renal Failure Progression. Renal Failure 2009;30:247-55. [DOI: 10.1080/08860220701856946] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
34 Wardle EN. Antioxidants in the Prevention of Renal Disease. Renal Failure 2009;21:581-91. [DOI: 10.3109/08860229909094152] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
35 Sharma AM, Pischon T, Engeli S, Scholze J. Choice of drug treatment for obesity-related hypertension: where is the evidence?: . Journal of Hypertension 2001;19:667-74. [DOI: 10.1097/00004872-200104000-00001] [Cited by in Crossref: 63] [Cited by in F6Publishing: 50] [Article Influence: 3.2] [Reference Citation Analysis]
36 Taylor AA, Sunthornyothin S. The case for combining angiotensinconverting enzyme inhibitors and calcium-channel blockers. Current Science Inc 1999;1:446-53. [DOI: 10.1007/s11906-999-0062-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]